InvestorsHub Logo

illmatix

08/10/17 11:55 AM

#29290 RE: chainma1l #29289

i wouldnt be so pessimistic, we can get another anda approval any day.

sales are good and rexista isnt dead, we just need the studies to prove anti abuse.

a partner could handle this and i dont htink there are no interested parties out there :)

greetz

doogdilinger

08/10/17 12:21 PM

#29294 RE: chainma1l #29289

Very interesting...perhaps IPCI sells off FocalinXR to PAR, sells off SeroquelXR and their other 2 already partnered with Mallinkrodt ANDA's to Mallinkrodt...and then sells off the rest of their remaining generics division and shifts the focus solely on PODRAS and their opioid based NDA's?

The only way that happens is if Dr. Odidi is willing to step aside and bring in a seasoned pro CEO to make that deal...while simultaneously freeing Dr. Odidi up to go all in on the science behind his novel nPODDS and PODRAS delivery tech platforms.

We already know from past presentations that Dr. Odidi has another 20 opioid based NDA's planned.

We already know from the ever changing landscape that the FDA screwed their entire generics pipeline from getting to market in a far more timely fashion anyways.

And we already know that the real money in IPCI's still evolving/emerging pipeline is in the opioid based NDA's and Dr. Odidi's nPODDS and PODRAS proprietary delivery tech platforms anyways.

There's a multitude of directions IPCI can go from here if Dr. Odidi's been humbled enough since the Rexista adcom rejection.